Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Precision Biosciences Inc (NASDAQ: DTIL) closed the day trading at $3.81 down -10.56% from the previous closing price of $4.26. In other words, the price has decreased by -$10.56 from its previous closing price. On the day, 0.53 million shares were traded. DTIL stock price reached its highest trading level at $4.49 during the session, while it also had its lowest trading level at $3.61.
Ratios:
For a better understanding of DTIL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.22 and its Current Ratio is at 9.22. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.45.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on April 30, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On June 17, 2022, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 27 ’24 when Buehler Kevin bought 4,320 shares for $4.88 per share. The transaction valued at 21,082 led to the insider holds 8,712 shares of the business.
Kelly John Alexander bought 2,113 shares of DTIL for $10,037 on Dec 27 ’24. The Chief Financial Officer now owns 40,186 shares after completing the transaction at $4.75 per share. On Dec 26 ’24, another insider, Brown Melinda, who serves as the Director of the company, bought 3,016 shares for $4.55 each. As a result, the insider paid 13,723 and bolstered with 7,218 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DTIL now has a Market Capitalization of 29226738 and an Enterprise Value of -41668264. As of this moment, Precision’s Price-to-Earnings (P/E) ratio for their current fiscal year is 74.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.35 while its Price-to-Book (P/B) ratio in mrq is 0.44. Its current Enterprise Value per Revenue stands at -0.555 whereas that against EBITDA is 3.479.
Stock Price History:
Over the past 52 weeks, DTIL has reached a high of $19.43, while it has fallen to a 52-week low of $4.13. The 50-Day Moving Average of the stock is -44.02%, while the 200-Day Moving Average is calculated to be -60.64%.
Shares Statistics:
Over the past 3-months, DTIL traded about 107.62K shares per day on average, while over the past 10 days, DTIL traded about 234980 shares per day. A total of 7.48M shares are outstanding, with a floating share count of 3.73M. Insiders hold about 8.12% of the company’s shares, while institutions hold 81.17% stake in the company. Shares short for DTIL as of 1734048000 were 274486 with a Short Ratio of 2.55, compared to 1731628800 on 239855. Therefore, it implies a Short% of Shares Outstanding of 274486 and a Short% of Float of 3.63.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2 analysts currently analyzing and rating the stock of Precision Biosciences Inc (DTIL).The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.39 and low estimates of -$0.39.
Analysts are recommending an EPS of between $1.57 and $0.49 for the fiscal current year, implying an average EPS of $1.03. EPS for the following year is -$8.62, with 2.0 analysts recommending between -$5.28 and -$11.96.
Revenue Estimates
4 analysts predict $4.28M in revenue for the current quarter. It ranges from a high estimate of $9.5M to a low estimate of $600k. As of the current estimate, Precision Biosciences Inc’s year-ago sales were $7.04MFor the next quarter, 4 analysts are estimating revenue of $10M. There is a high estimate of $10M for the next quarter, whereas the lowest estimate is $10M.
A total of 5 analysts have provided revenue estimates for DTIL’s current fiscal year. The highest revenue estimate was $77.5M, while the lowest revenue estimate was $68.06M, resulting in an average revenue estimate of $71.45M. In the same quarter a year ago, actual revenue was $48.73MBased on 4 analysts’ estimates, the company’s revenue will be $20.02M in the next fiscal year. The high estimate is $45.6M and the low estimate is $5M.
